JP2023511403A5 - - Google Patents
Info
- Publication number
- JP2023511403A5 JP2023511403A5 JP2022544649A JP2022544649A JP2023511403A5 JP 2023511403 A5 JP2023511403 A5 JP 2023511403A5 JP 2022544649 A JP2022544649 A JP 2022544649A JP 2022544649 A JP2022544649 A JP 2022544649A JP 2023511403 A5 JP2023511403 A5 JP 2023511403A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- antibody fragment
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964747P | 2020-01-23 | 2020-01-23 | |
| US62/964,747 | 2020-01-23 | ||
| PCT/US2021/014790 WO2021151020A1 (en) | 2020-01-23 | 2021-01-22 | Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511403A JP2023511403A (ja) | 2023-03-17 |
| JP2023511403A5 true JP2023511403A5 (enExample) | 2024-01-19 |
Family
ID=76992835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544649A Pending JP2023511403A (ja) | 2020-01-23 | 2021-01-22 | 条件的に活性な抗ｈｅｒ２抗体、抗体断片、それらの免疫コンジュゲート、およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230109218A1 (enExample) |
| EP (1) | EP4093774A4 (enExample) |
| JP (1) | JP2023511403A (enExample) |
| KR (1) | KR20220131937A (enExample) |
| CN (1) | CN115943164A (enExample) |
| AU (1) | AU2021210412A1 (enExample) |
| CA (1) | CA3165662A1 (enExample) |
| IL (1) | IL294829A (enExample) |
| MX (1) | MX2022009138A (enExample) |
| TW (1) | TW202140559A (enExample) |
| WO (1) | WO2021151020A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085781A1 (en) | 2023-10-19 | 2025-04-24 | Genentech, Inc. | Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers |
| WO2025254460A1 (ko) * | 2024-06-07 | 2025-12-11 | ㈜지아이이노베이션 | Cd80 단백질 및 il-2 단백질을 포함하는 융합단백질 및 항체-약물 접합체를 포함하는 암 치료용 약학 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289942B1 (en) * | 2002-04-10 | 2013-07-31 | Genentech, Inc. | Anti-HER2 antibody variants |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
| US9777067B2 (en) * | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| KR101936697B1 (ko) * | 2013-11-19 | 2019-01-10 | 레메젠 리미티드 | 항-her2 항체 및 이의 접합체 |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| EP3083696B1 (en) * | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| US11058768B2 (en) * | 2014-04-16 | 2021-07-13 | Biocon Ltd. | Stable protein formulations comprising a molar excess of sorbitol |
| WO2015164723A1 (en) * | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| CN107787331B (zh) * | 2015-06-17 | 2022-01-11 | 豪夫迈·罗氏有限公司 | 抗her2抗体和使用方法 |
| EP3740505A1 (en) * | 2018-01-16 | 2020-11-25 | Lakepharma Inc. | Bispecific antibody that binds cd3 and another target |
| WO2019241216A1 (en) * | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
-
2021
- 2021-01-22 JP JP2022544649A patent/JP2023511403A/ja active Pending
- 2021-01-22 US US17/759,195 patent/US20230109218A1/en active Pending
- 2021-01-22 CN CN202180012021.3A patent/CN115943164A/zh active Pending
- 2021-01-22 EP EP21744106.2A patent/EP4093774A4/en active Pending
- 2021-01-22 MX MX2022009138A patent/MX2022009138A/es unknown
- 2021-01-22 KR KR1020227026938A patent/KR20220131937A/ko active Pending
- 2021-01-22 IL IL294829A patent/IL294829A/en unknown
- 2021-01-22 WO PCT/US2021/014790 patent/WO2021151020A1/en not_active Ceased
- 2021-01-22 AU AU2021210412A patent/AU2021210412A1/en active Pending
- 2021-01-22 CA CA3165662A patent/CA3165662A1/en active Pending
- 2021-01-22 TW TW110102594A patent/TW202140559A/zh unknown